AGL 31.35 Increased By ▲ 0.15 (0.48%)
AIRLINK 143.00 Increased By ▲ 0.30 (0.21%)
BOP 5.12 Increased By ▲ 0.04 (0.79%)
CNERGY 4.11 Increased By ▲ 0.07 (1.73%)
DCL 9.49 Decreased By ▼ -0.21 (-2.16%)
DFML 49.51 Decreased By ▼ -0.69 (-1.37%)
DGKC 79.10 Decreased By ▼ -0.40 (-0.5%)
FCCL 22.75 Decreased By ▼ -0.30 (-1.3%)
FFBL 46.78 Increased By ▲ 0.68 (1.48%)
FFL 9.57 Increased By ▲ 0.52 (5.75%)
HUBC 153.49 Decreased By ▼ -0.01 (-0.01%)
HUMNL 11.29 Decreased By ▼ -0.18 (-1.57%)
KEL 4.17 Increased By ▲ 0.03 (0.72%)
KOSM 9.26 Decreased By ▼ -1.01 (-9.83%)
MLCF 33.30 Decreased By ▼ -0.30 (-0.89%)
NBP 58.70 Increased By ▲ 1.85 (3.25%)
OGDC 136.75 Decreased By ▼ -0.50 (-0.36%)
PAEL 25.88 Increased By ▲ 1.43 (5.85%)
PIBTL 6.05 Increased By ▲ 0.08 (1.34%)
PPL 112.35 Decreased By ▼ -0.65 (-0.58%)
PRL 24.38 Increased By ▲ 0.03 (0.12%)
PTC 11.88 Decreased By ▼ -0.07 (-0.59%)
SEARL 57.40 Decreased By ▼ -0.36 (-0.62%)
TELE 7.77 Increased By ▲ 0.17 (2.24%)
TOMCL 41.99 Increased By ▲ 0.11 (0.26%)
TPLP 8.49 Decreased By ▼ -0.16 (-1.85%)
TREET 15.23 Increased By ▲ 0.13 (0.86%)
TRG 51.50 Decreased By ▼ -0.95 (-1.81%)
UNITY 28.00 Increased By ▲ 0.14 (0.5%)
WTL 1.42 Increased By ▲ 0.08 (5.97%)
BR100 8,340 Decreased By -5.8 (-0.07%)
BR30 26,956 Increased By 47.9 (0.18%)
KSE100 78,898 Increased By 34.4 (0.04%)
KSE30 25,008 Decreased By -18.2 (-0.07%)
World

Oxford says COVID-19 vaccine 76pc effective for 3 months after one shot

  • AstraZeneca has welcomed the move, saying flexibility to extend the time between doses is the best strategy for the shot.
Published February 2, 2021

LONDON: The COVID-19 vaccine developed by Oxford University and AstraZeneca has 76pc efficacy against symptomatic infection for three months after a single dose, with greater effectiveness when a second is given later, a study showed on Tuesday.

Oxford University said the findings of the pre-print paper, which had not been peer-reviewed, supported Britain's decision to extend the interval between initial and booster doses of the shot to 12 weeks.

Britain has decided to give as many people as possible some protection by lengthening the amount of time between initial shots and booster shots of COVID-19 vaccines.

AstraZeneca has welcomed the move, saying flexibility to extend the time between doses is the best strategy for the shot.

The results, gathered from trials in Britain, Brazil and South Africa, indicated some protection was given after one shot and that immune responses were boosted with a longer interval to the second dose among participants aged 18 to 55 years.

"Vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 post vaccination was 76pc, and modelled analysis indicated that protection did not wane during this initial 3 month period," Oxford academics said.

The paper said that vaccine efficacy was 82.4pc with 12 or more weeks to the second dose, compared to 54.9pc for those where the booster was given under 6 weeks after the first dose.

Comments

Comments are closed.